Skip to main content

MANGOCEUTICALS INC

For the period ended Mar 31, 2024. Filed May 15, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

MGRX$0.20+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

The following exhibits are filed herewith or incorporated by reference herein:

Filed/ · Incorporated by Reference
Exhibit · Description of · Furnished · Filing · File
Number · Exhibit · Herewith · Form · Exhibit · Date · Number
3.1Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., submitted to the Secretary of State of Texas on March 28, 202410-K3.34/1/2024001-41615
3.2Certificate of Designations, Preferences and Rights of 6% Series C Convertible Preferred Stock of Mangoceuticals, Inc., filed with the Secretary of State of Texas on April 19, 20248-K3.14/25/2024001-41615
3.3Certificate of Correction to Certificate of Designations, Preferences and Rights of 6% Series C Convertible Preferred Stock of Mangoceuticals, Inc., filed with the Secretary of State of Texas on April 29, 20248-K3.15/2/2024001-41615
4.1Common Stock Purchase Warrant issued by Mangoceuticals, Inc. to Boustead Securities, LLC on January 22, 20248-K4.11/22/2024001-41615
4.2Common Share Purchase Warrant dated April 4, 2024 (3,300,000 shares), granted to Platinum Point Capital LLC8-K4.14/11/2024001-41615
10.1#Mangoceuticals, Inc. 2022 Equity Incentive Plan Stock Option Agreement dated December 28, 2023 - Jacob Cohen - 1,250,000 shares8-K10.201/02/2024001-41615
10.2#First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan8-K10.103/26/2024001-41615
10.3#Amended and Restated Mangoceuticals, Inc. 2022 Equity Incentive Plan8-K10.203/26/2024001-41615
10.4£Securities Purchase Agreement dated April 4, 2024, entered into between Mangoceuticals, Inc. and Platinum Point Capital LLC8-K10.14/11/2024001-41615
10.5£Equity Purchase Agreement dated April 4, 2024, entered into between Mangoceuticals, Inc. and Platinum Point Capital LLC8-K10.24/11/2024001-41615
10.6Registration Rights Agreement (SPA), dated April 4, 2024, entered into between Mangoceuticals, Inc. and Platinum Point Capital LLC8-K10.34/11/2024001-41615
10.7Registration Rights Agreement (ELOC), dated April 4, 2024, entered into between Mangoceuticals, Inc. and Platinum Point Capital LLC8-K10.44/11/2024001-41615
10.8Patent Purchase Agreement dated April 24, 2024, by and between Mangoceuticals, Inc., as purchaser and Intramont Technologies, Inc., as seller8-K10.14/25/2024001-41615
31.1*Certification of Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a)X
31.2*Certification of Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a)X
32.1**Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350X
32.2**Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350X
101.INSInline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL documentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document SetX
  • Filed herewith.

** Furnished herein.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.